Literature DB >> 29203659

TRPV1 is a physiological regulator of μ-opioid receptors.

Paul C Scherer1, Nicholas W Zaccor1, Neil M Neumann2, Chirag Vasavda1, Roxanne Barrow1, Andrew J Ewald2, Feng Rao3, Charlotte J Sumner1,4, Solomon H Snyder5,6,7.   

Abstract

Opioids are powerful analgesics, but also carry significant side effects and abuse potential. Here we describe a modulator of the μ-opioid receptor (MOR1), the transient receptor potential channel subfamily vanilloid member 1 (TRPV1). We show that TRPV1 binds MOR1 and blocks opioid-dependent phosphorylation of MOR1 while leaving G protein signaling intact. Phosphorylation of MOR1 initiates recruitment and activation of the β-arrestin pathway, which is responsible for numerous opioid-induced adverse effects, including the development of tolerance and respiratory depression. Phosphorylation stands in contrast to G protein signaling, which is responsible for the analgesic effect of opioids. Calcium influx through TRPV1 causes a calcium/calmodulin-dependent translocation of G protein-coupled receptor kinase 5 (GRK5) away from the plasma membrane, thereby blocking its ability to phosphorylate MOR1. Using TRPV1 to block phosphorylation of MOR1 without affecting G protein signaling is a potential strategy to improve the therapeutic profile of opioids.

Entities:  

Keywords:  G protein-coupled receptor kinase 5; G protein-coupled receptors; opiates; transient receptor potential vanilloid 1; μ-opioid receptor

Mesh:

Substances:

Year:  2017        PMID: 29203659      PMCID: PMC5754810          DOI: 10.1073/pnas.1717005114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

2.  Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing.

Authors:  Dmitry Usoskin; Alessandro Furlan; Saiful Islam; Hind Abdo; Peter Lönnerberg; Daohua Lou; Jens Hjerling-Leffler; Jesper Haeggström; Olga Kharchenko; Peter V Kharchenko; Sten Linnarsson; Patrik Ernfors
Journal:  Nat Neurosci       Date:  2014-11-24       Impact factor: 24.884

3.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

4.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

5.  Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells.

Authors:  Daniel J Cavanaugh; Alexander T Chesler; Alexander C Jackson; Yaron M Sigal; Hiroki Yamanaka; Rebecca Grant; Dajan O'Donnell; Roger A Nicoll; Nirao M Shah; David Julius; Allan I Basbaum
Journal:  J Neurosci       Date:  2011-03-30       Impact factor: 6.167

6.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

7.  Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases.

Authors:  R T Premont; W J Koch; J Inglese; R J Lefkowitz
Journal:  J Biol Chem       Date:  1994-03-04       Impact factor: 5.157

8.  Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5.

Authors:  Laura Glück; Anastasia Loktev; Lionel Moulédous; Catherine Mollereau; Ping-Yee Law; Stefan Schulz
Journal:  Biol Psychiatry       Date:  2014-02-03       Impact factor: 13.382

9.  Pharmacological assessment of m1 muscarinic acetylcholine receptor-gq/11 protein coupling in membranes prepared from postmortem human brain tissue.

Authors:  Hasib Salah-Uddin; David R Thomas; Ceri H Davies; Jim J Hagan; Martyn D Wood; Jeannette M Watson; R A John Challiss
Journal:  J Pharmacol Exp Ther       Date:  2008-03-05       Impact factor: 4.030

Review 10.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

View more
  11 in total

1.  The nonselective cation channel TRPV4 inhibits angiotensin II receptors.

Authors:  Nicholas W Zaccor; Charlotte J Sumner; Solomon H Snyder
Journal:  J Biol Chem       Date:  2020-06-03       Impact factor: 5.157

2.  Targeting G protein-coupled receptor kinases (GRKs) to G protein-coupled receptors.

Authors:  Sarah M Sulon; Jeffrey L Benovic
Journal:  Curr Opin Endocr Metab Res       Date:  2020-09-18

3.  Restoring glutamate homeostasis in the nucleus accumbens via endocannabinoid-mimetic drug prevents relapse to cocaine seeking behavior in rats.

Authors:  Lan-Yuan Zhang; Yue-Qing Zhou; Zhi-Peng Yu; Xiao-Qin Zhang; Jie Shi; Hao-Wei Shen
Journal:  Neuropsychopharmacology       Date:  2021-01-29       Impact factor: 8.294

4.  β-Arrestin 2 and ERK1/2 Are Important Mediators Engaged in Close Cooperation between TRPV1 and µ-Opioid Receptors in the Plasma Membrane.

Authors:  Barbora Melkes; Vendula Markova; Lucie Hejnova; Jiri Novotny
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

5.  Myrcene and terpene regulation of TRPV1.

Authors:  C Jansen; L M N Shimoda; J K Kawakami; L Ang; A J Bacani; J D Baker; C Badowski; M Speck; A J Stokes; A L Small-Howard; H Turner
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

6.  Chemokine CCL2 prevents opioid-induced inhibition of nociceptive synaptic transmission in spinal cord dorsal horn.

Authors:  Mario Heles; Petra Mrozkova; Dominika Sulcova; Pavel Adamek; Diana Spicarova; Jiri Palecek
Journal:  J Neuroinflammation       Date:  2021-12-02       Impact factor: 8.322

Review 7.  Side Effects of Opioids Are Ameliorated by Regulating TRPV1 Receptors.

Authors:  Xiaqing Wang; Chongyu Bao; Zhenjiang Li; Lupeng Yue; Li Hu
Journal:  Int J Environ Res Public Health       Date:  2022-02-18       Impact factor: 3.390

8.  Repeated Morphine Administration Increases TRPV1 mRNA Expression and Autoradiographic Binding at Supraspinal Sites in the Pain Pathway.

Authors:  Thi-Lien Nguyen; Yun-Son Nam; Seok-Yong Lee; Choon-Gon Jang
Journal:  Biomol Ther (Seoul)       Date:  2022-05-26       Impact factor: 4.231

9.  Itch induced by peripheral mu opioid receptors is dependent on TRPV1-expressing neurons and alleviated by channel activation.

Authors:  Helvira Melo; Lilian Basso; Mircea Iftinca; Wallace K MacNaughton; Morley D Hollenberg; Derek M McKay; Christophe Altier
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

Review 10.  Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.

Authors:  Wolfgang Sadee; John Oberdick; Zaijie Wang
Journal:  Molecules       Date:  2020-09-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.